Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. oral res. (Online) ; 32: e114, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-974440

RESUMO

Abstract Smokers have a risk of developing periodontal disease. Matrix metalloproteinases (MMP) play a significant role in periodontal tissue destruction. In this study possible relationship between smoking and gingival tissue expression of gelatinases in chronic periodontitis patients relative to periodontally healthy subjects was investigated. Forty chronic periodontitis patients (20 smokers and 20 non-smokers) and forty periodontally healthy subjects (20 smokers and 20 non-smokers) were enrolled. The clinical periodontal measurements recorded, and gingival tissues harvested after that. After histologic evaluation, matrix metalloproteinases -2 and -9 expressions were analyzed immunohistochemically. In nonsmokers, higher expression of metalloproteinases -2 and -9 detected in chronic periodontitis group compared to the periodontally healthy group. In the smoker chronic periodontitis group, the expression of metalloproteinases-2 was lower than nonsmoker chronic periodontitis group. Statistically significant differences detected between smoker and nonsmoker periodontally healthy groups in metalloproteinases-2 expression. For metalloproteinases-9 expression, smoker chronic periodontitis group has lower values than nonsmoker chronic periodontitis group. In periodontally healthy group smokers showed higher metalloproteinases -9 expressions than non- smokers. Present findings support the role of gelatinases in chronic periodontitis pathogenesis. Based on the current results we conclude that smoking alters the expression of gelatinases in gingival tissues.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Fumar/efeitos adversos , Metaloproteinase 2 da Matriz/análise , Metaloproteinase 9 da Matriz/análise , Periodontite Crônica/enzimologia , Biópsia , Imuno-Histoquímica , Estudos de Casos e Controles , Estudos Transversais , Análise de Variância , Estatísticas não Paramétricas , Fibroblastos/enzimologia , Gengiva/enzimologia , Pessoa de Meia-Idade
2.
Braz. oral res. (Online) ; 31: e15, 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-839515

RESUMO

Abstract Anorganic bovine bone mineral (ABBM) is extensively used in the treatment of intra-bony defects. Platelet-rich fibrin (PRF) is a new-generation platelet concentrate with a simplified technique. Although certain studies have reported the use of PRF in the treatment of intra-bony defects, to date, none of them have evaluated its additive effects with ABBM. Therefore, a randomised, split-mouth clinical trial was conducted to compare healing of intra-bony defects treated with an ABBM-PRF combination with healing of those treated with ABBM alone. By using a split-mouth design, 15 paired intra-bony defects were randomly treated with either ABBM alone (control group) or ABBM-PRF combination (test group). Following clinical parameters and radiographical measurements were recorded at baseline and 6 months after treatment: plaque index (PI), gingival index (GI), probing depth (PD), gingival recession (GR), clinical attachment level (CAL), vertical bone loss, depth of defect and defect angle. Preoperative clinical and radiographical measurements were similar for the test and control groups. Statistically significant reductions in GI, PD, CAL, vertical bone loss, depth of intra-bony defect and widening of defect angle were detected after treatment in both groups. With respect to inter-group analysis, gain in CAL was significantly greater in the test group than in the control group, whereas no inter-group differences were observed in any other parameter. The results of this study indicate that both therapies are effective in the treatment of intra-bony defects.


Assuntos
Humanos , Animais , Masculino , Feminino , Adulto , Bovinos , Cicatrização/efeitos dos fármacos , Plaquetas , Regeneração Óssea/efeitos dos fármacos , Fibrina/uso terapêutico , Perda do Osso Alveolar/terapia , Substitutos Ósseos/uso terapêutico , Fatores de Tempo , Índice Periodontal , Índice de Placa Dentária , Reprodutibilidade dos Testes , Perda do Osso Alveolar/diagnóstico por imagem , Resultado do Tratamento , Terapia Combinada , Estatísticas não Paramétricas , Retração Gengival
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA